Baidu
map

Hepatology:HCV通过巨噬细胞激活肝星状细胞介导CCL5分泌

2017-03-29 MedSci MedSci原创

背景:HCV引起的慢性肝病是当前严重的健康问题,常引起纤维化/肝硬化及肝细胞癌。尽管炎症反应被认为在疾病的发生中发挥重要作用,但HCV感染期间肝脏疾病进展的具体机制尚不清除。方法:我们先前报道了包括Kuffer细胞在内的巨噬细胞暴露在HCV时,产生前炎症细胞因子。这些细胞因子可激活肝星状细胞致纤维化。在本研究中,我们研究了在HCV感染是巨噬细胞同肝星状细胞的相互作用。原代人肝星状细胞及永生的肝星状

背景:HCV引起的慢性肝病是当前严重的健康问题,常引起纤维化/肝硬化及肝细胞癌。尽管炎症反应被认为在疾病的发生中发挥重要作用,但HCV感染期间肝脏疾病进展的具体机制尚不清除。

方法:我们先前报道了包括Kuffer细胞在内的巨噬细胞暴露在HCV时,产生前炎症细胞因子。这些细胞因子可激活肝星状细胞致纤维化。在本研究中,我们研究了在HCV感染是巨噬细胞同肝星状细胞的相互作用。原代人肝星状细胞及永生的肝星状细胞(LX2细胞系)使用暴露HCV的人巨噬细胞的处理的培养基培养。

结果:通过检测这些细胞中炎症及纤维化相关的基因,发现炎症标记物(NLRP3, IL-1β, IL-6 and CCL5)和前纤维生成的标记物(TGFβ1, COL4A1, MMP2 and α-SMA)表达均上升。进一步研究发现,暴露HCV下的巨噬细胞分泌的CCL5激活肝星状细胞炎症小体及纤维化标记物,CCL5中和抗体可移植星状细胞激活。

结论:研究结果证实暴露HCV的人巨噬细胞可介导CCL5分泌,在感染炎症和纤维化中发挥显着作用。

原始出处:

Reina Sasaki,Pradip B. Devhare,Robert Steele,et al.Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells. Hepatology,20 March 2017,DOI: 10.1002/hep.29170

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682294, encodeId=4f7e16822949d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Oct 05 11:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773110, encodeId=f7b51e7311045, content=<a href='/topic/show?id=7ebb812317c' target=_blank style='color:#2F92EE;'>#肝星状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81231, encryptionId=7ebb812317c, topicName=肝星状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c7a38475595, createdName=tulenzi, createdTime=Sat Jul 15 18:00:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257663, encodeId=09b8125e663f2, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426708, encodeId=011c1426e0833, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631344, encodeId=f11a163134488, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=)]
    2017-10-05 gwc392
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682294, encodeId=4f7e16822949d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Oct 05 11:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773110, encodeId=f7b51e7311045, content=<a href='/topic/show?id=7ebb812317c' target=_blank style='color:#2F92EE;'>#肝星状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81231, encryptionId=7ebb812317c, topicName=肝星状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c7a38475595, createdName=tulenzi, createdTime=Sat Jul 15 18:00:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257663, encodeId=09b8125e663f2, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426708, encodeId=011c1426e0833, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631344, encodeId=f11a163134488, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682294, encodeId=4f7e16822949d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Oct 05 11:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773110, encodeId=f7b51e7311045, content=<a href='/topic/show?id=7ebb812317c' target=_blank style='color:#2F92EE;'>#肝星状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81231, encryptionId=7ebb812317c, topicName=肝星状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c7a38475595, createdName=tulenzi, createdTime=Sat Jul 15 18:00:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257663, encodeId=09b8125e663f2, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426708, encodeId=011c1426e0833, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631344, encodeId=f11a163134488, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=)]
    2017-03-30 ymljack
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682294, encodeId=4f7e16822949d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Oct 05 11:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773110, encodeId=f7b51e7311045, content=<a href='/topic/show?id=7ebb812317c' target=_blank style='color:#2F92EE;'>#肝星状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81231, encryptionId=7ebb812317c, topicName=肝星状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c7a38475595, createdName=tulenzi, createdTime=Sat Jul 15 18:00:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257663, encodeId=09b8125e663f2, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426708, encodeId=011c1426e0833, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631344, encodeId=f11a163134488, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=)]
    2017-03-30 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1682294, encodeId=4f7e16822949d, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Oct 05 11:00:00 CST 2017, time=2017-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773110, encodeId=f7b51e7311045, content=<a href='/topic/show?id=7ebb812317c' target=_blank style='color:#2F92EE;'>#肝星状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81231, encryptionId=7ebb812317c, topicName=肝星状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c7a38475595, createdName=tulenzi, createdTime=Sat Jul 15 18:00:00 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257663, encodeId=09b8125e663f2, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426708, encodeId=011c1426e0833, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631344, encodeId=f11a163134488, content=<a href='/topic/show?id=e210421640' target=_blank style='color:#2F92EE;'>#CCL5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4216, encryptionId=e210421640, topicName=CCL5)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d621719915, createdName=lingqf, createdTime=Thu Mar 30 15:00:00 CST 2017, time=2017-03-30, status=1, ipAttribution=)]
    2017-03-30 lingqf

相关资讯

J Gastroenterol:日本人群中Elbasvir 联合grazoprevir 治疗HCV:II/III期临床研究

背景:Elbasvir (EBR)联合grazoprevir (GZR)治疗HCV感染业已证实有效,然而临床研究主要在美国和欧洲进行。我们旨在研究EBR和GZR在日本伴或不伴有肝脏硬化的HCV患者中的安全性和有效性。方法:研究分为两个部分。第一部分,不伴有肝硬化的患者按照1:1的比例随机接受EBR 50mg+GZR 50mg或EBR 50mg+GZR 100mg治疗12周。第二部分,不伴有肝硬化患

hepatology:等待肝脏移植患者治疗HCV的更佳时机

口服直接抗病毒药物的出现业已改变了肝脏移植前或肝脏移植后的丙型肝炎病毒治疗模式。移植前或移植后抗丙型肝炎病毒治疗需要进行权衡,因为抗丙肝病毒治疗可改善肝脏功能,继而降低了肝脏移植的必要性。我们研究旨在识别基于MELD评分适合肝脏移植的肝硬化失代偿患者移植前治疗将会从中获益(或不获益)。我们模拟了一个虚拟的试验,对比MELD评分在10-40之间的患者肝脏移植前或肝脏移植后使用口服直接抗病毒药物治疗丙

plos pathogen:HCV突变如何逃逸免疫系统的追捕?

与A型以及B型肝炎病毒不同,HCV如今在全球范围内造成了170万人的感染,但却一直没有开发出成功的疫苗。如今,来自约翰霍普金斯大学的研究者们利用新型的试验手段发现病毒的突变的速度以及成功率要远远高于人们的想象,同时,他们发现了HCV突变的生物学机制,这一机制或许解释了HCV能够逃脱免疫系统以及

快速一览:近期丙肝病毒(HCV)研究汇总

我国丙肝防治在认知率、诊断率、治疗率以及药物可及性、可负担性等多方面都落后于乙肝。消除丙肝应以疾病教育为根本,同时从治疗突破,让患者在实现治愈的同时获益于生命质量的提升。丙型肝炎病毒(HCV)可缓慢发展多年,通常无症状,但可引起严重的肝损伤和肝癌。梅斯小编针对HCV研究最近取得的进展,作了一番盘点,与大家分享。【1】NEJM:抗病毒治疗可防止肝移植导致的丙肝病毒再感染 根据一项西北医

Ann Intern Med:FDA批准的口服DAA药物有很高的HCV治愈率

2017年3月21日/生物谷BIOON/---丙型肝炎由丙型肝炎病毒(HCV)感染所致,主要由血液/体液传播。据世界卫生组织估计,全球有1.7亿人感染HCV。在我国健康人群抗HCV阳性率为0.7%~3.1%,约3800万人。由于病毒生物学特点和宿主免疫功能等多方面因素,机体免疫往往难以有效清除病毒,致使约50%~80%HCV感染者发展为慢性肝炎,其中20%~30%将发展成肝硬化。肝

Hepatology:他汀再添新作用:降低HBV、HCV肝硬化患者失代偿风险

背景:他汀类药物降低由HCV导致的肝硬化患者功能失代偿及死亡风险。然而,这种收益是否可拓展到普通人群,或者诸如HBV和酒精性肝硬化尚不清除。他汀同样也可降低HBV和HCV感染患者肝细胞癌的发生风险。这种作用是否能够在已经存在肝硬化的患者出现也不清除。我们旨在识别他汀在降低HBV、HCV或酒精性肝硬化患者肝功能失代偿、死亡率的作用。方法:从台湾国家医疗保险受益者中选取肝硬化患者。累积限定日剂量大于等

Baidu
map
Baidu
map
Baidu
map